Investing.com - Financial Markets Worldwide

Poxel SA (POXEL)

Paris
Currency in EUR
0.33
+0.02(+6.40%)
Closed·
POXEL Scorecard
Full Analysis
Net income is expected to grow this year
POXEL is not included in our AI-picked strategies. See which stocks are.
Fair Value
Unlock Value
Day's Range
0.310.34
52 wk Range
0.120.83
Key Statistics
Edit
Prev. Close
0.31
Open
0.31
Day's Range
0.31-0.34
52 wk Range
0.12-0.83
Volume
344.38K
Average Volume (3m)
695.25K
1-Year Change
-45.02%
Book Value / Share
-1.04
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
POXEL Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Technical Analysis
Strong Sell
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Unlock All 10
Analysts anticipate sales growth in the current year
Unlock InvestingPro

Poxel SA News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Buy
Moving Averages
Sell

Poxel SA Company Profile

Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company’s lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH); PXL065, an earlier stage programs that is in Phase 2 for the treatment of NASH focusing on chronic and rare metabolic indications. The company has a licensing agreement with Enyo Pharma S.A.S. for the development of farnesoid X receptor that is in Phase 2a study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial dysfunction; and Sumitomo Pharma for development and commercialization of Imeglimin. Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France.

Industry
Biotechnology & Medical Research
Sector
Healthcare
Employees
6
Market
France

Compare POXEL to Peers and Sector

Metrics to compare
POXEL
Peers
Sector
Relationship
P/E Ratio
−1.9x−2.0x−0.6x
PEG Ratio
−0.020.020.00
Price/Book
−0.6x1.5x2.6x
Price / LTM Sales
14.0x3.9x3.3x
Upside (Analyst Target)
-130.5%38.7%
Fair Value Upside
Unlock17.7%5.1%Unlock

Earnings

Latest Release
May 20, 2025
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
a
a
Unlock
Last 90 days

POXEL Income Statement

People Also Watch

Valneva
3.832
VLS
+1.54%
Adocia
8.78
ADOC
+15.22%
Blockchain Group SA
1.8680
ALCPB
+7.60%
EssilorLuxottica
263.40
ESLX
-1.16%
Teleperformance
67.28
TEPRF
-2.32%

FAQ

What Stock Exchange Does Poxel SA Trade On?

Poxel SA is listed and trades on the Paris Stock Exchange stock exchange.

What Is the Stock Symbol for Poxel SA?

The stock symbol for Poxel SA is "POXEL."

What Is the Poxel SA Market Cap?

As of today, Poxel SA market cap is 17.71M.

What Is Poxel SA's Earnings Per Share (TTM)?

The Poxel SA EPS (TTM) is -0.41.

When Is the Next Poxel SA Earnings Date?

Poxel SA will release its next earnings report on 22 Sept 2025.

From a Technical Analysis Perspective, Is POXEL a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Poxel SA Stock Split?

Poxel SA has split 0 times.

How Many Employees Does Poxel SA Have?

Poxel SA has 6 employees.

What is the current trading status of Poxel SA (POXEL)?

As of 28 Aug 2025, Poxel SA (POXEL) is trading at a price of 0.33, with a previous close of 0.31. The stock has fluctuated within a day range of 0.31 to 0.34, while its 52-week range spans from 0.12 to 0.83.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.